Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis - A comprehensive meta-analysis

被引:255
作者
Richy, F
Bruyere, O
Ethgen, O
Cucherat, M
Henrotin, Y
Reginster, JY
机构
[1] Univ Liege, Fac Med, Dept Publ Hlth & Epidemiol, Liege, Belgium
[2] WHO, Collaborating Ctr Publ Hlth Aspects Osteoarticula, Bone & Cartilage Metab Res Unit, Liege, Belgium
[3] Cochrane French Ctr, Lyon, France
关键词
D O I
10.1001/archinte.163.13.1514
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To assess the structural and symptomatic efficacy of oral glucosamine sulfate and chondroitin sulfate in knee osteoarthritis through independent meta-analyses of their effects on joint space narrowing, Lequesne Index, Western Ontario MacMaster University Osteoarthritis Index (WOMAC), visual analog scale for pain, mobility, safety, and response to treatment. Methods: An exhaustive systematic research of randomized, placebo-controlled clinical trials published or performed between January 1980 and March 2002 that assessed the efficacy of oral glucosamine or chondroitin on gonarthrosis was performed using MEDLINE, PREMEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Current Contents, BIOSIS Previews, Health-STAR, EBM Reviews, manual review of the literature and congressional abstracts, and direct contact with the authors and manufacturers of glucosamine and chondroitin. Inclusion, quality scoring, and data abstraction were performed systematically by 2 independent reviewers who were blinded to sources and authors. Conservative approaches were used for clear assessment of potential efficacy. Results: Our results demonstrated a highly significant efficacy of glucosamine on all outcomes, including joint space narrowing and WOMAC. Chondroitin was found to be effective on Lequesne Index, visual analog scale pain, mobility, and responding status. Safety was excellent for both compounds. Conclusions: Our study demonstrates the structural efficacy of glucosamine and indistinguishable symptomatic efficacies for both compounds. Regarding the relatively sparse data on glucosamine and joint space narrowing and the absence of data on structural effects of chondroitin, further studies are needed to investigate the relationship among time, dose, patient baseline characteristics, and structural efficacy for an accurate, disease-modifying characterization of these 2 compounds.
引用
收藏
页码:1514 / 1522
页数:9
相关论文
共 65 条
[1]  
Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905
[2]  
[Anonymous], 1997, OSTEOARTHR CARTILAGE
[3]  
[Anonymous], 1997, METAANALYSE ESSAIS T
[4]  
BELLAMY N, 1988, J RHEUMATOL, V15, P1833
[5]  
BLOTMAN F, 1993, OSTEOARTHR CARTILAGE, V1, P68
[6]   Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo [J].
Bourgeois, P ;
Chales, G ;
Dehais, J ;
Delcambre, B ;
Kuntz, JL ;
Rozenberg, S .
OSTEOARTHRITIS AND CARTILAGE, 1998, 6 :25-30
[7]  
Buckland-Wright JC, 1999, J RHEUMATOL, V26, P2664
[8]   Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis [J].
Bucsi, L ;
Poór, G .
OSTEOARTHRITIS AND CARTILAGE, 1998, 6 :31-36
[9]   Beyond disability: measuring the social and personal consequences of osteoarthritis [J].
Carr, AJ .
OSTEOARTHRITIS AND CARTILAGE, 1999, 7 (02) :230-238
[10]   SOME METHODS FOR STRENGTHENING THE COMMON X2 TESTS [J].
COCHRAN, WG .
BIOMETRICS, 1954, 10 (04) :417-451